Situation Assessment

• AngioChem is a clinical-stage biotechnology company discovering and developing breakthrough drugs that are uniquely capable of crossing the blood- brain barrier to treat brain diseases.
• Lead program, ANG1005, a novel taxane derivative, demonstrated impressive clinical activity in patients with primary and metastatic brain tumors.
• Engaged Locust Walk Partners as its exclusive commercial and business development advisor.

Key Activities

• Developed a comprehensive commercial assessment which included conducting primary market research among physicians and payors. Formulated high-impact revenue model that was instrumental in forming partners’ perceptions of overall opportunity and for negotiating deal terms.
• Led an outreach to a targeted list of leading global and regional companies active in the development and commercialization of oncology products.
• Led multiple parties through a confidential diligence process leading to competing term sheets.
• Conducted face-to-face negotiations of the term sheet and definitive agreement.

Successful Outcome

• Competitive negotiations process resulted in $35M upfront and undisclosed milestones and royalties for an exclusive global partnership for GRN1005 (formerly ANG1005).
• Transaction also included a multi-year research collaboration for Geron’s proprietary telomerase inhibitor.